Akums Drugs has announced that it has been granted a patent for its invention titled “Dual Release Gastro-Resistant Composition.” The patent is valid for 20 years, starting from November 19, 2022, under the provisions of the Patents Act, 1970.
This marks a significant milestone for the company as it introduces a next-generation Dual Release Proton Pump Inhibitor (PPI) tablet, designed to treat patients suffering from moderate to severe or treatment-resistant Gastroesophageal Reflux Disease (GERD) — one of the most common digestive disorders worldwide.
GERD affects about 14% of the global population, which translates to nearly 784 million people as of 2019. In India alone, studies suggest a prevalence rate of around 15.6%. The condition occurs when stomach acid repeatedly flows back into the esophagus, causing discomfort and heartburn.
Traditional PPIs like Pantoprazole and Esomeprazole are widely used to reduce stomach acid, but they often fail to provide sustained relief, especially at night. Akums’ new Dual Release PPI tablet addresses this limitation by releasing the medicine in two phases — half in the duodenum and the other half in the ileum. This allows for extended absorption and a longer duration of action, providing better control over acid reflux and ensuring more heartburn-free days.
Developed using Akums’ unique tablet-in-tablet technology, the formulation ensures improved stability, consistent drug release, and enhanced effectiveness. The once-daily tablet has also received approval from the Drugs Controller General of India (DCGI).
